Solubility of calcium salts and their effect on osteoporosis.
Cayón
E
E
Medical Department, Merck Farma y Química, S.A., Barcelona, Spain.
Roquer
M
M
D002119:Calcium Carbonate / Q000737:chemistry*; D002130:Calcium Phosphates / Q000737:chemistry*; D002136:Calcium, Dietary / Q000378:metabolism; D017886:Durapatite / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D008956:Models, Chemical; D010024:Osteoporosis / Q000378:metabolism; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D012995:Solubility
D002130:Calcium Phosphates; D002136:Calcium, Dietary; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C092985:calcium pidolate; C485838:calcium phosphate, monobasic, anhydrous; D017886:Durapatite; C020243:calcium phosphate; D002119:Calcium Carbonate; C485829:calcium phosphate, dibasic, anhydrous; D011761:Pyrrolidonecarboxylic Acid